We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Rhumbline Advisers trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 1.5% in the fourth quarter, according to its most recent filing with the Securities and ...

Ieq Capital LLC purchased a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the 4th quarter, Holdings Channel reports. The fund purchased 10,163 shares of the ...

Blueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...

SM Market Opportunity: Projected peak value of $4 billion, with AYVAKIT as the anchor. Blueprint Medicines Corp (NASDAQ:BPMC) ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chemomab Therapeutics (CMMB – Research Report) ...

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.

BLUEPRINT MEDICINES ($BPMC) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of -$0.79 per share, missing estimates of -$0. ...